The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at an assay dependent concentration. Detection limit for recombinant tagged CCNL1 is approximately 3ng/ml as a capture antibody.
ICC/IF: Use at a concentration of 10 µg/ml.
WB: Use at a concentration of 1 - 5 µg/ml. Detects a band of approximately 18 kDa (predicted molecular weight: Isoform 5 (Cyclin L gamma) 18kDa; Longest Isoform (Cyclin L alpha) 60 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionTranscriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II). Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21.
Tissue specificityUbiquitous with higher level in thymus. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC).
Sequence similaritiesBelongs to the cyclin family. Cyclin L subfamily.
DomainContains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions.
Cellular localizationNucleus speckle. More specifically found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing.